Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive the company has completed a constructive pre-Investigational New Drug (IND) application meeting with the US Food and Drug Administration (FDA) for its IHL-675A proprietary drug targeted at the treatment of rheumatoid arthritis (RA). IHL-675A is a combination of cannabidiol (CBD) and hydroxychloroquine sulphate designed to address inflammatory disorders including RA. A successful IND application is a requirement to conduct trials in the US and ensures trials are designed to meet data requirements for future FDA approvals.
Incannex thrilled with positive pre-IND meeting for arthritis treatment
